T1	Premise 866 950	There were no serious events with the 1 + 2.5 dosage or after ccHRT discontinuation.
T2	Premise 951 1040	Climacteric symptoms remained significantly below baseline values after dosage reduction;
T3	Premise 1041 1095	some symptoms recurred after discontinuation of ccHRT.
T4	Premise 1096 1228	HRQOL ratings improved with ccHRT, irrespective of dosage, including depressed mood, anxiety, health perception and sexual interest.
T5	Premise 1229 1330	Scores on a scale assessing daily functioning and enjoyment (Q-LES-Q) improved from year 7 to year 9.
T6	Premise 1331 1396	They deteriorated during follow-up in women not continuing ccHRT.
T7	Claim 1397 1534	Lower dosages of HRT were as effective as higher doses in improving climacteric symptoms and HRQOL ratings and had fewer safety concerns.
T8	Premise 1535 1680	Following discontinuation of ccHRT, patient satisfaction was variable, with 15% electing to continue or restart HRT and 7% resuming at follow-up.
T9	Claim 1681 1762	This supports the need for an individualized approach to therapy recommendations.
R1	Support Arg1:T4 Arg2:T7	
R2	Support Arg1:T2 Arg2:T7	
R3	Support Arg1:T5 Arg2:T7	
R4	Support Arg1:T7 Arg2:T9	
R5	Support Arg1:T1 Arg2:T7	
